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In rectal cancer, preoperative staging should identify early tumours suitable for treatment by surgery alone and locally advanced
tumours that require therapy to induce tumour regression from the potential resection margin. Currently, local staging can be
performed by digital rectal examination (DRE), endoluminal ultrasound (EUS) or magnetic resonance imaging (MRI). Each staging
method was compared for clinical benefit and cost-effectiveness. The accuracy of high-resolution MRI, DRE and EUS in identifying
favourable, unfavourable and locally advanced rectal carcinomas in 98 patients undergoing total mesorectal excision was compared
prospectively against the resection specimen pathological as the gold standard. Agreement between each staging modality with
pathology assessment of tumour favourability was calculated with the chance-corrected agreement given as the kappa statistic, based
on marginal homogenised data. Differences in effectiveness of the staging modalities were compared with differences in costs of the
staging modalities to generate cost effectiveness ratios. Agreement between staging and histologic assessment of tumour favourability
was 94% for MRI (k¼ 0.81, s.e.¼ 0.05; kW¼ 0.83), compared with very poor agreements of 65% for DRE (k¼ 0.08, s.e.¼ 0.068,
kW¼ 0.16) and 69% for EUS (k¼ 0.17, s.e.¼ 0.065, kW¼ 0.17). The resource benefits resulting from the use of MRI rather than DRE
was d67164 and d92244 when MRI was used rather than EUS. Magnetic resonance imaging dominated both DRE and EUS on cost
and clinical effectiveness by selecting appropriate patients for neoadjuvant therapy and justifies its use for local staging of rectal cancer
patients.
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Meticulous surgical technique, as exemplified by total mesorectal
excision (TME), has improved survival by reducing local
recurrences in patients undergoing resection with curative intent
(Heald, 1995; Carlsen et al, 1998). In addition, preoperative
neoadjuvant radiotherapy and chemoradiotherapy regimens also
promise to improve survival (Marsh et al, 1994; Anonymous, 1997;
Pahlman et al, 1998; Dahlberg et al, 1999), but their success needs
to be tempered against the inevitable morbidity associated with
such treatments (Dahlberg et al, 1998). In 1997, the Scandinavian
rectal cancer trials (Anonymous, 1997) showed that preoperative
therapy reduced local recurrence rates in patients undergoing
rectal cancer surgery. This effect was also shown in patients
undergoing TME with significantly reduced local recurrence rates
in patients undergoing TME surgery plus preoperative radio-
therapy compared with patients undergoing TME surgery alone
(Kapiteijn et al, 2001). However, preoperative short-course radio-
therapy had no effect on local recurrence rates in patients with
positive circumferential resection margin (CRM) status. Both trials
suggest that preoperative radiotherapy can reduce local recurrence
rates compared with surgery alone, but it is clear that the
magnitude of the benefit is very small if such treatments are used
unselectively (van de Velde, 2002).
In order to improve patient selection, a preoperative staging
method is required to identify early stage tumours that are suitable
for treatment by surgery alone as well as more advanced tumours
that require more intensive therapy than short-course radio-
therapy to enable tumour regression from the potential surgical
resection margins. Clinical assessment by digital rectal examina-
tion (DRE) and endoluminal ultrasound (EUS) are recommended
as a method of making this preoperative assessment (1996).
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It has previously been shown that using a high-resolution
technique, thin slice magnetic resonance imaging (MRI) can be
used to measure the depth of extramural spread accurately with
good correlation with corresponding pathology measurements
in resection specimens (Brown et al, 1999). Furthermore, the
relationship of tumour to the mesorectal fascia can be seen so that
CRM positive status is predicted when tumour is imaged within
1 mm of the mesorectal fascia (Brown et al, 2003a). However, MRI
is generally regarded as an expensive modality that has not proven
clinically effective or cost-effective in oncology imaging. Given that
DRE and EUS are widely available and are the current standards
for preoperative assessment of local tumour stage in many centres,
a prospective comparison of the clinical value of MRI in staging
rectal cancer patients over these techniques was performed.
In this study, the accuracy of high-resolution MRI, DRE and
EUS in identifying favourable, unfavourable and locally advanced
rectal carcinomas was compared prospectively against the gold
standard of the pathological findings in the resection specimens.
The potential impact of each staging modality on the preoperative
treatment pathway was then compared, for clinical benefit and
cost-effectiveness.
MATERIALS AND METHODS
Patients
Patients with biopsy diagnosed rectal cancer referred our
institution were eligible for informed consent to participate in
this study. This study was performed according to a protocol
approved by the Ethics Committee of our institution and informed
consent was obtained from each patient.
Digital rectal examination was performed as an outpatient
clinical assessment by the consultant colorectal surgeon (AGR,
BIR) as the initial assessment of the primary tumour. Colonoscopy
examination findings and examination under general anaesthesia
were not included in the analysis of clinical effectiveness nor in the
costings.
The fixity of the tumour was recorded as mobile, tethered or
fixed according to criteria of Nicholls et al (1985). EUS and MRI
were undertaken within 2 weeks of TME surgery. A total of 26
women and 72 men (age range 28–89 years) consented to enter the
study over a 3-year period.
Imaging technique
Both EUS and MRI examinations were performed with knowledge
of the height of the tumour from the anal verge but without
knowledge of any other investigation findings.
EUS was performed by a single observer (JB, a consultant
radiologist experienced in EUS) using a 7.5/10 MHz radial
scanning transducer with water filled probe cover. EUS staging
was performed according to established criteria (Beynon et al,
1986) using the T and N components of the TNM classification. For
T3 and T4 tumours, the maximum depth of spread in mm beyond
the muscularis propria was recorded.
T2-weighted MRI was performed (Brown et al, 1999). The
tumour was staged according to the TNM classification and the
maximum depth of extramural spread was recorded using criteria
developed previously (Brown et al, 1999, 2003b). In addition, note
was made of the relationship of tumour (either in continuity with
the primary mass or as a separate mesorectal deposit (Brown et al,
2003b) with an irregular border or a mixed intensity signal) to the
mesorectal fascia. Cases with tumour reaching within 1 mm of this
landmark, or beyond it, were defined as CRM positive.
In assessing extramural spread, cases were classified into
favourable stage, unfavourable or locally advanced stage (depend-
ing on T stage and nodal status) and advanced stage (if the
potential CRM was at risk). Table 1 shows the criteria for allocating
patients into these three local stage categories and the therapeutic
plan resulting from this evaluation.
Treatment schedules
TME surgery was performed in all cases, with sphincter sparing
anterior resection in 75 patients and abdominoperineal excision in
23 patients. Patients judged to have favourable tumours were
treated with surgery only. Those with unfavourable tumours
received a 1-week course of preoperative radiotherapy of 25 Gy in
five fractions in 5 days using a three field technique on 10 Mv
linear accelerators in the week immediately preceding surgery
(Anonymous, 1997). Patients with locally advanced, clinically
inoperable tumours were given a long course of radiotherapy using
a three field planned treatment to the posterior pelvis giving 45 Gy
in 25 fractions over 5 weeks in combination with infusional 5FU
(200 mg m2 throughout radiotherapy) followed by surgery. DRE,
EUS and MRI were performed at baseline and repeated within 2
weeks prior to surgery to provide data for correlation with the
resection specimen.
Pathology
Pathological staging was undertaken by a consultant pathologist
according to the TNM classification and the pathological extent of
maximal extramural spread in mm and the distance of tumour to
the nearest CRM was measured.
Table 1 Preoperative stage groupings using DRE, EUS and MRI
Favourable No favourable features identified Locally advanced
DRE Mobile (1) Mobile o5 cm from anal verge Fixed
(2) Tethered tumour
(3) Not assessable due to pain or beyond DRE and
sigmoidoscopic assessment of mobility
EUS T1N0, T2N0 or 0T3o1 mm N0 Node positive T4
T341 mm
Tumour not assessable due to bulk or location
beyond the edge of the probe
MRI T1N0, T2N0 or T3o1 mm N0 Node positive T4 or tumour p1 mm from mesorectal fascia
T341 mm
Histopathology pT1N0, pT2N0 or pT3o1 mm N0 Node positive pT4 or tumour p1 mm from the CRM
T341 mm
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Cost analysis
The costs of staging for rectal cancer depend on which perspective
is employed and include staff time, equipment costs, running
costs, overheads, patients costs, etc. In addition, there are the
implications of successful and accurate staging and more
pertinently the cost implications resulting from unsuccessful and
inaccurate staging. The implications of unsuccessful and inaccu-
rate staging on resource utilisation and patients’ quality of life are
extensive. For this analysis, calculations were restricted to the
impact on preoperative radiotherapy budgets.
The treatment strategy model employed recommendations from
the Swedish rectal cancer (Anonymous, 1997) trial and the Dutch
TME trial (Kapiteijn et al, 2001), which are summarised in Table 1.
Thus, all operable patients are eligible to receive short-course
high-dose preoperative radiotherapy (25 Gy in five fractions over 5
days) but favourable tumours defined as node negative: T1, T2 or
T3a cases that can undergo curative resection by optimised surgery
alone. In addition, patients considered to have locally advanced
disease receive long-course radiotherapy (45 Gy in 25 fractions
over 5 weeks).
Estimates of the local procedure costs for EUS and MRI were
adjusted to account for variation in other centres in the sensitivity
analysis. The costs of short- and long-course radiotherapy and
chemotherapy sessions were obtained from the participating
oncology centre, Velindre Hospital (Table 2). The costs of
overstaging (d2538) were based on the cost of preoperative
adjuvant treatment provided unnecessarily, while the costs of
understaging were based on estimates of treatment for recurrences
in the literature (Neymark and Adriaenssen, 1999) (assumed to be
between d8460 and d14 840) multiplied by the probability of
recurrence (30%) (Frykholm et al, 1995). The differences in rates
of effectiveness for the staging modalities were used to generate
comparisons of the resource implications, in terms of radiotherapy
costs for the 98 patients studied.
Cost effectiveness
Differences in rates of effectiveness of the staging modalities were
compared with differences in the costs of the staging modalities to
generate cost effectiveness ratios and a series of one-way
sensitivity analyses were carried out on the baseline findings.
Statistical methods
Agreement between EUS, MRI or DRE with pathology assessment
of tumour favourability was calculated with the chance-corrected
agreement given as the kappa statistic, based on marginal
homogenised data (Scott, 1955).
RESULTS
The study cohort represented a consecutive series of patients
referred with rectal cancer consenting to take part in the study
from two surgical centres in one city. In total, 23 patients had
tumour o6 cm to the anal verge, 12 had tumour wholly above the
peritoneal reflection and the remainder were located in the mid-
rectum. Assessment of tumour mobility was achieved in 74
patients, the remaining 24 having tumours that were too high or
too painful to assess by DRE. Only 54 were adequately evaluated by
EUS: five patients were unassessable due to failed bowel
preparation, the full length of the tumour was beyond the EUS
probe in 28 and the remaining 11 patients experienced severe pain
or declined the procedure. All 98 patients tolerated the MRI
examination.
In total, 48 operable patients underwent resection within 2
weeks of clinical and radiological assessment. A further 44 patients
underwent short-course high-dose preoperative radiotherapy and
six patients with clinically inoperable tumours received long-
course preoperative chemoradiotherapy.
Clinical effectiveness
Pathological examination of resected specimens showed 31
patients to have favourable tumours (T1, T2, T3o1 mm spread
beyond the outer longitudinal muscle coat and N0 disease), 39
patients having unfavourable (T341 mm or node positive), and
the remaining 28 patients having locally advanced tumours (pT4
or CRM positive). Table 3 shows the agreement between each of
the staging modalities with the pathology gold standard.
Preoperative identification of favourable prognosis
tumours
Digital rectal examination correctly identified 22 out of 31 (71%)
patients with favourable prognosis tumours. Four favourable
prognosis mobile tumours were not identified because tumour
sited high in the rectum was beyond the reach of DRE. In a further
three cases apparent tethering on clinical examination indicating
more extensive extramural spread was not confirmed on
histological examination. In two cases low bulky tumours that
were deemed fixed on clinical assessment were confined to the
rectal wall on subsequent histopathological assessment. Review of
both cases on MR imaging showed bulky polypoidal tumours
adjacent to a markedly enlarged prostate gland.
Table 2 Procedure and radiotherapy costs
Procedure costs d
DRE 0
EUS 78
MRI 130
Adjuvant therapy
Radiotherapy session 84
Chemotherapy session 180
Short-course radiotherapy treatment (5 sessions) 420
Long-course radiotherapy treatment (25 sessions) 2100
Table 3 DRE, EUS and MRI assessment of ‘correct’ preoperative
treatment strategy vs histopathology gold standard
Histopathology
Favourable Unfavourable Locally advanced Total
DRE assessment
Surgery alone 22 22 7 51
Short-course RT 7 14 18 39
Long course RT 2 3 3 8
Total 31 39 28 98
EUS assessment
Surgery alone 14 5 8 27
Short-course RT 17 32 19 68
Long course RT 0 2 1 3
Total 31 39 28 98
MRI assessment
Surgery alone 31 5 2 38
Short-course RT 0 33 4 37
Long-course RT 0 1 22 23
Total 31 39 28 98
Values in bold indicate number of cases showing agreement with histopathology.
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Endoluminal ultrasound correctly identified 14 of 31 (45%)
favourable prognosis tumours. In two patients, extramural depth
had been substantially overestimated. In both cases, large
intraluminal tumour masses had been located in the upper rectum.
Review of the study showed that the size and position of the
tumour had resulted in tangential placement of the probe against
the tumour. The resultant obliquity of the probe had produced
artefactual loss of the outer muscle coat resulting in overestimation
of tumour depth. In the remaining 15 patients, failure to reach
tumour using the EUS probe resulted in inability to assess tumour
depth.
Magnetic resonance imaging correctly identified all patients
with favourable prognosis tumours (example shown in Figure 1);
however, it was noted that in nine out of 31 patients there was
overlap between MR and histology assessment of T2 vs T3o1 mm
spread.
Preoperative identification of unfavourable prognosis
tumours
Histopathological examination showed tumour extension into
perirectal fat and/or node-positive status in 39 patients. Clinical
assessment correctly identified 14 out of 39 (36%). In 22 out of 39
patients clinical assessment judged tumours as mobile and nine
out of 22 showed tumour spread 45 mm into perirectal fat that
was not clinically tethered. In three out of 39 patients, clinical
staging suggested tumour fixation. Corresponding MR imaging in
these three patients showed extramural low signal intensity
indicating fibrosis and subsequent histopathological assessment
confirmed extensive peritumoral fibrosis and inflammatory change
as a cause of apparent fixation on DRE.
EUS assessment resulted in the correct identification of 32 out of
39 (82%) patients with unfavourable prognosis tumours. Two
patients that had been endoscopically overstaged were shown on
EUS as showing invasion of adjacent bladder and prostate. In both
cases hyporeflective tumour produced loss of definition of the
borders between rectum and adjacent organ. These changes were
shown to relate to extramural fibrosis but not tumour. In three
cases staged as favourable tumours by EUS, nodal metastases were
not detected by EUS. On review of the pathology specimens, the
nodal metastases were sited 430 mm from the bowel wall and thus
not encompassed within the EUS field of view. In two further cases,
both low bulky tumours, extramural tumour depth of 41 mm had
been underestimated.
Using MRI, 33 out of 39 (85%) unfavourable prognosis tumours
were correctly identified (example shown in Figure 2). In one
Figure 1 Favourable tumour. High-resolution T2-weighted fast spin-echo image and corresponding histological (H&E stained) wholemount section. The
tumour (arrow) is depicted as a U-shaped polypoidal mass of intermediate signal intensity. The muscualris propria is of lower signal intensity (arrow head)
and does not appear breached by tumour indicating tumour confined to bowel wall (T2). The corresponding wholemount histology section confirms that
this is a T2 tumour.
Figure 2 Unfavourable prognosis tumour. High-resolution T2-weighted fast spin-echo image and corresponding histological (H&E stained) wholemount
section. The MRI scan shows widespread discontinuous tumour deposits (arrows) (representing either nodes replaced by tumour or tumour satellites)
within the mesorectum, but not extending to the mesorectal fascia (arrow heads). This is confirmed as node-positive disease on corresponding wholemount
histology section.
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patient, positive nodes were shown on MRI to lie within 1 mm of
the mesorectal fascia and therefore classified as advanced
(potential CRM positive), but subsequent histological examination
showed that this distance was 2 mm (CRM negative) indicating this
was unfavourable tumour. In two cases, node-positive status
indicating unfavourable prognosis tumour was not detected by
MRI. In each of these cases, the tumour was within 5 cm of the anal
verge and imaging had not encompassed the upper third of the
mesorectum containing these positive nodes. In the remaining
three out of 39 patients, tumour spread 41 mm had been
underestimated by MRI.
Preoperative identification of locally advanced tumours
There were 28 cases with pathological features indicating locally
advanced disease. Only three of these were successfully identified
by clinical staging. Of these 28 cases, 18 were classified as
unfavourable: five were too high for clinical assessment, six
tumours were mobile and less than 5 cm from the anal verge and
seven tumours tethered on examination, but on subsequent
histopathology examination showed extensive extramural spread
or nodes involving the CRM. A further seven were classified as
favourable as they were clinically mobile and 45 cm from the anal
verge.
Only one locally advanced case was successfully identified using
EUS. In this case, low tumour with invasion into the levator was
demonstrated. In 12 patients, tumour was unassessable because
tumour could not be reached by the probe or because of pain
experienced by the patient. In 15 patients, tumour deposits
involving the mesorectal fascia resulting in positive CRM had not
been identified.
Of 28 patients, 22 with locally advanced tumours were
successfully identified using MRI (example shown in Figure 3).
In four patients, nodes close to the mesorectal fascia had not been
detected. In each of these cases the nodes were partially replaced
by small tumour foci that were not resolved on MR images. In two
patients tumour was thought to have breached the wall anteriorly
by o1 mm, but histopathologic examination showed stage pT4
peritoneal infiltration by tumour.
There was a high level of agreement between MRI and histologic
assessment of tumour favourability (94%) (k¼ 0.81, standard
error¼ 0.05; weighted k¼ 0.83). This compared with very poor
agreement between DRE and histologic assessment of tumour
favourability (65%) (k¼ 0.08, standard error¼ 0.068, weighted
k¼ 0.16), and a poor level of agreement between EUS and
histologic assessment of tumour favourability (69%) (k¼ 0.17,
standard error¼ 0.065, weighted k 0.17).
Treatment
Table 4 indicates the impact these errors in staging would have in
clinical practice given the three different treatment schedules in
the model. On DRE staging alone, 51 patients would have had
surgery alone, 39 short-course RT and eight long-course RT. In
comparison with the gold standard, 22, 14 and three patients in
each treatment group respectively were appropriately selected
(40%). The remainder would have been either under or over
treated.
On EUS staging, 47 patients (48%) would have been correctly
selected, while using MRI 86 patients (88%) would have had the
appropriate treatment selected.
The costs incurred as a result of incorrect preoperative
treatment on the basis of either DRE, EUS and MRI assessment
are shown in Table 4. The resource benefits that accompany each
additional successful and accurately staged patient amount to
d1282 if MRI is used instead of DRE and d1195 if MRI is used
instead of EUS, indicating that MRI is a cost-effective technique.
The total costs incurred (procedure costs and costs resulting
from incorrect preoperative treatment) from staging the 98
patients using the three modalities are shown in Table 5. The
resource benefits that result from the use of MRI rather than DRE
amount to d67164 and d92244 when MRI is used rather than EUS.
In addition, MRI correctly staged 86 patients, 47 more than DRE
and 39 more than EUS. In terms of cost-effectiveness MRI
dominates both DRE and EUS on the grounds of cost and
effectiveness.
Sensitivity analysis
Assuming the resource implications of understaging are zero This
scenario assumes that there are no resource implications resulting
from understaging. The total cost of staging using MRI amounts to
d15204 compared with d54150 using EUS and d27006 for DRE.
Therefore, MRI dominates both DRE and EUS in terms of cost and
effectiveness.
Increasing the cost of an MRI to d500 Given the variation in the
alleged cost of an MRI, this scenario assumes that the cost of an
MRI is d500. The cost of staging 98 patients using MRI (including
the resource implications from incorrect staging) then amounts to
Figure 3 Locally advanced tumour. High-resolution T2-weighted fast spin-echo image and corresponding histological (H&E stained) wholemount section.
This shows tumour extending beyond the bowel wall and involving the potential left lateral resection margin (arrow). Margin involvement is confirmed on
subsequent histopathological section (arrow).
Effectiveness of preoperative staging in rectal cancer
G Brown et al
27
British Journal of Cancer (2004) 91(1), 23 – 29& 2004 Cancer Research UK
C
li
n
ic
a
l
d68008 – a resource difference of d56768 compared with EUS and
d31688 compared with DRE. Thus, in order for the total cost for
MRI to equate with EUS (taking into account the resource
implications of incorrect staging), the cost of an MRI procedure
would need to be substantially higher, that is, d1079.
Only including procedure costs If only procedure costs were
included and the resource implications resulting from incorrect
staging ignored, the total cost for EUS would be d7644 and for MRI
the cost would be d13 524, a difference of d5880. For this additional
expenditure there are 39 more patients who are successfully and
accurately staged by using MRI than EUS and 47 when compared
with DRE. This produces a cost per additional successful and
accurately staged patient of d151 when using MRI rather than EUS
and d288 when compared with DRE. When the procedure cost of
MRI is d500 the cost per additional correctly staged patient is
d1060 (MRI vs EUS) and d1043 (MRI vs DRE), which appears to
represent a good investment, given that the cost of treating
recurrence is d8460 and we have assumed that the probability of
recurrence for understaging is 30%.
DISCUSSION
This study, employing meticulous histopathological assessment of
tumour staging as the gold standard, clearly demonstrates the
benefits of thin slice, T2 weighted, high-resolution MRI over both
DRE and EUS for staging rectal cancer preoperatively. The study
highlights the value of employing a noninvasive technique as
inability to assess high rectal tumours hampered the accuracy of
both EUS and DRE in identifying favourable, unfavourable and
advanced tumours of the upper rectum. MRI was able to accurately
identify all favourable prognosis tumours regardless of height from
the anal verge. This improved accuracy of assessment translates
into better patient selection by diminishing the use of needless and
potentially harmful neoadjuvant therapy in patients with node
negative status ando1 mm extramural tumour spread who have a
favourable prognosis (Willett et al, 1999). Moreover, the MRI
images allow visualisation of the whole of the tumour, its
anatomical disposition in any plane extramurally, and its relation-
ship to the CRM, all of which greatly assist the planning of any
preoperative radiotherapy and the surgical resection itself.
While there is growing evidence that preoperative radiotherapy
and TME have an additive (Holm et al, 1997) effect on
improvement of local recurrence rates, it is becoming clear that
preoperative radiotherapy for ‘good’ prognosis patients is over-
treatment that wastes resources and leads to significant morbidity.
Many studies have shown that the depth of extramural invasion,
nodal involvement and CRM involvement are independent
markers of poor prognosis (Cawthorn et al, 1986; Jass and Love,
1989; Adam et al, 1994; Hall et al, 1998) and selection for
neoadjuvant therapy is being increasingly based on these. MRI
performs particularly well over other modalities in the assessment
of these parameters and studies have prospectively validated the
technique for accuracy of depth of extramural spread and its
ability to predict CRM involvement (Brown et al, 1999, 2003a). By
contrast, DRE (which depends on the subjective appreciation of
tumour mobility or fixity) performs poorly, understaging 47% of
cases. EUS tends to overestimate tumour depth (Akasu et al, 1996)
due to the obliquity of the probe in relation to the lesion and
difficulty in separating peritumoural inflammation or fibrosis from
true tumour (Maier et al, 1997). No previous EUS studies have
assessed its accuracy in TME specimens yet, in the present study,
its inherent small field of view limited its usefulness in assessing
the whole mesorectum. Neither nodes/tumour deposits located
within the mesorectum at a distance from the bowel lumen nor the
mesorectal fascia (representing the potential CRM) were visua-
lised. Thus, neither EUS nor DRE were able to assess discontin-
uous mesorectal tumour deposits that might govern operability for
cure, and both are invasive, potentially painful modalities that
cannot be applied to all patients for technical reasons.
Relatively few early lesions occurred in this study (representing
our typical experience of symptomatic rectal cancer). This may
account for the relatively poor performance of EUS at T staging.
The assessment of early tumours by EUS was outside the scope of
this study.
Table 4 costs incurred as a result of incorrect preoperative treatment on the basis of either DRE, EUS and MRI assessment
DRE EUS MRI
Treatment cost
Number of
patients Total cost d
Number of
patients Total cost d
Number of
patients Total cost d
Long-course RT instead of short-course RT
(d1680 per incorrectly staged patient)
3 5040 2 3360 1 1680
Short-course instead of long-course RT (d2538
per incorrectly staged patient)
18 45 684 19 48 222 4 10 152
Long-course RT instead of surgery alone
(d2100 per incorrectly staged patient)
2 4200 0 0 0 0
Surgery alone instead of long-course RT
(d2538 per incorrectly staged patient)
7 17 766 8 20 304 2 5076
Surgery alone instead of short course RT (d420
per incorrectly staged patient)
22 9240 5 2100 5 2100
Short-course RT instead of surgery alone
(d2538 per incorrectly staged patient)
7 17 766 17 43 146 0 0
Total incorrectly staged 59 99 696 51 117 132 12 19 008
Table 5 Total costs of staging using three modalities
DRE EUS MRI
Procedure costs 0 7644 13 524
Costs of incorrect staging 99 696 117 132 19 008
Total costs 99 696 124 776 32 532
Total cost per staged patient 1017 1273 332
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Nevertheless, MRI appeared to be poor at separating T1 from T2
tumours and in distinguishing sessile or polypoid adenomas from
T1 adenocarcinomas, whereas others have shown that EUS has
been is highly accurate in the assessment of early tumours
(Akasu et al, 2000). Clearly, EUS has an important and
complementary role in staging early lesions. Our data therefore
suggest that MRI is a poor technique for selecting patients for local
excision, but future studies should address the role of EUS in this
subgroup of patients.
MRI shows clear clinical benefits over the traditional method
using combined DRE and EUS in terms of correct allocation of
patients to treatment groups for radiotherapy and/or chemother-
apy. Accordingly, MRI results in significant treatment cost benefits
that are very likely to offset the costs of the procedure itself as well
as being more clinically effective than the alternatives.
Thus, the advantages of preoperative high-resolution MRI in
selecting appropriate patients for neoadjuvant therapy justify its
routine use in the local staging of rectal cancer patients.
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